Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) EPS (Basic) : ¥-0.47 (TTM As of Sep. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co EPS (Basic)?

Staidson (Beijing) Biopharmaceuticals Co's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was ¥-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-0.47.

Staidson (Beijing) Biopharmaceuticals Co's EPS (Diluted) for the three months ended in Sep. 2024 was ¥-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥-0.47.

Staidson (Beijing) Biopharmaceuticals Co's EPS without NRI for the three months ended in Sep. 2024 was ¥-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -0.46.

During the past 3 years, the average EPS without NRI Growth Rate was -40.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Staidson (Beijing) Biopharmaceuticals Co's highest 3-Year average EPS without NRI Growth Rate was 132.30% per year. The lowest was -61.80% per year. And the median was 14.90% per year.

Staidson (Beijing) Biopharmaceuticals Co EPS (Basic) Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co EPS (Basic) Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

0.06

-0.28

-0.29

-0.41

-0.84

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.07	-0.45	-0.01	-	-0.01

Staidson (Beijing) Biopharmaceuticals Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Staidson (Beijing) Biopharmaceuticals Co's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-398.893	-	0)	/	474.872
	=	-0.84

Staidson (Beijing) Biopharmaceuticals Co's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5.942	-	0)	/	468.248
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.47

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Staidson (Beijing) Biopharmaceuticals Co EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Staidson (Beijing) Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176

Website

http://www.staidson.com

Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.

Executives

Zhang Hong Shan	Supervisors
Zheng Hong	Supervisors
Cheng Jiang Hong	Executives
Feng Yu Jing	Executives
Ma Li Na	Secretary, Director
Zhou Zhi Wen	Director
Wang Huan	Securities Affairs Representative
Zhang Rong Qin	Executives
Xu Jiang Ping	Executives
Cao Hai Yan	Supervisors
Sun Yan Fang	Executives
Jiang Li Xin	Director
Gu Jian Ping	Director
Xu Xiang Qing	Supervisors
Gu Zhen Qi	Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines